Sentinel — Overview
PILLAR 5 · CONTINUOUS MONITORING DURING ACTIVE TREATMENT
Sentinel is OnKommon's continuous monitoring service for people on active treatment for advanced cancer. Cancer evolves under therapy — it can adapt and become resistant. Sentinel watches the tumour over time from repeat blood draws, confirming that treatment is working and — crucially — catching resistance early, often before a scan would show the cancer moving.
2 · Why continuous monitoring
Sentinel watches your cancer over time — so you know when to stay the course and when to pivot.
See treatment working
Falling ctDNA is an early sign a therapy is doing its job.
Catch resistance early
A rising signal, or a new resistance mutation, can appear before imaging changes — buying time to switch.
Change the plan sooner
Molecular progression can prompt a timely pivot, rather than staying on a failing therapy.
3 · The Sentinel Alert workflow
From signal to action — fast.
Red flag
A rising ctDNA trend or a new resistance mutation is detected on a scheduled draw.
Clinical briefing
KPCIRC reviews the finding in the context of your treatment and history.
Counter-attack
The engine surfaces evidence-based next options — a switch, a combination, or a trial.
Seamless transition
Your navigator helps you move to the next line of treatment without losing time.
4 · Sentinel vs Clear
Active treatment vs remission surveillance.
Sentinel
Sentinel is for active treatment of advanced disease — watching therapy work and catching resistance. Choose Sentinel while on treatment.
Clear
Clear is for after curative-intent treatment — watching for any return (MRD). Choose Clear during remission surveillance.
5 · The two Sentinel tests
Sentinel Blood or Sentinel Solid — choose the right test for your cancer.
Sentinel Blood
- For: Blood-based / haematological monitoring
- Sample: Blood draw
- Watches for: Response & specific molecular markers
Sentinel Solid
- For: Solid tumours on active treatment
- Sample: Blood draw
- Watches for: Response, molecular progression & resistance
6 · Subscription & pricing
Track 2 / 4 / 6 · ₹88,000–₹1,00,000 per draw
RESEARCH & EVIDENCE
The science behind this
Sentinel uses serial ctDNA monitoring — evidence shows tracking the trend can reveal both response and resistance ahead of imaging.
Study 1 · Early switching on ctDNA improved outcomes
Serial blood monitoring detected rising ESR1 resistance mutations during hormone therapy; switching treatment as soon as the mutation appeared — before scans changed — improved progression-free survival.
Study 2 · Early ctDNA change predicts response
In metastatic gastrointestinal cancers, the change in ctDNA soon after starting therapy predicted radiographic response and progression-free survival.
Study 3 · Molecular progression precedes imaging
In real-world advanced-cancer monitoring, a rise in ctDNA often signalled progression before it was visible on scans — lead time to change a failing treatment.
These independent, peer-reviewed studies describe the class of technology OnKommon uses. They are shared for education; they are not results for any individual and are not a promise of benefit.
TERMINOLOGY ON THIS PAGE
The words you will see, in plain language
TRANSPARENCY — WHAT WE DO AND DON'T
Being clear about our limits
What we DO
- Track whether active treatment is working over time
- Catch resistance and molecular progression early
- Trigger KPCIRC review and a timely next-line plan
- Match cadence to need via Track 2 / 4 / 6
What we DON'T do
- Diagnose or switch therapy on its own — KPCIRC decides
- Detect every change (some tumours shed little ctDNA)
- Replace your scans and oncologist review
- Guarantee that an earlier switch will improve the outcome
Sentinel is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A "not detected" or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →